IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)-Reference-Cited by-同舟云学术

IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

Published:2019-10 Issue: Volume:30 Page:v710-v711
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Reck M.,Liu S.V.,Mansfield A.S.,Mok T.S.K.,Scherpereel A.,Reinmuth N.,Garassino M.C.,De Carpeno JCastro,Califano R.,Nishio M.,Orlandi F.,Alexander J A Alatorre,Leal T.A.,Cheng Y.,Lee J.-S.,Lam S.,McCleland M.,Deng Y.,Phan S.,Horn L.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz264/30085352/mdz264.pdf

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents;Cancer Management and Research;2024-07

2. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points;Journal of Cancer Research and Clinical Oncology;2024-05-15

3. Thymic carcinoid with multiple bone metastases: A case report;World Journal of Clinical Cases;2024-05-06

4. Transitioning to a Personalized Approach in Molecularly Subtyped Small-Cell Lung Cancer (SCLC);International Journal of Molecular Sciences;2024-04-10

5. Predictive biomarkers for immunotherapy response in extensive-stage SCLC;Journal of Cancer Research and Clinical Oncology;2024-01